The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2023 | Pre-clinical study on the dual BCL2/BCL-XL inhibitor AZD0466 for the treatment of CLL
BCL2 inhibitors (BCL2i) have revolutionized the treatment paradigm in chronic lymphocytic leukemia (CLL), with venetoclax commonly being administered in both the frontline and relapsed/refractory (R/R) setting. However, some patients develop resistance due to mutations in BCL2 and deregulation of apoptotic pathways. Stephan Stilgenbauer, MD, University of Ulm, Ulm, Germany, highlights the need for developing novel agents that will allow for the treatment of patients with resistance to BCL2i and presents the findings of a pre-clinical study of AZD0466, a dual BCL-2/BCL-XL inhibitor. The agent has demonstrated promising efficacy in lab models and can be combined with other agents, such as BTK inhibitors. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: Amgen, Abbvie, Celgene, Gilead, GSK, Roche, Janssen, Novartis, Sunesis, AstraZeneca; Honoraria: Amgen, Abbvie, Celgene, Gilead, GSK, Roche, Janssen, Novartis, Sunesis, AstraZeneca; Travel support: Amgen, Abbvie, Celgene, Gilead, GSK, Roche, Janssen, Novartis, Sunesis, AstraZeneca; Research Funding: Amgen, Abbvie, Celgene, Gilead, GSK, Roche, Janssen, Novartis, Sunesis, AstraZeneca.
